Add two more Abbott Laboratories diabetes products to the list of items deemed potentially deadly by the FDA. Five of the company's diabetes offerings have now been subject to the agency's most serious recall label in the past year.
Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
Abbott Laboratories has wrapped up enrollment in a 2,000-patient trial designed to win FDA approval for Absorb, its dissolvable vascular scaffold, setting sights on the world's largest market after charting success abroad.
In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Five days after the FDA announced it would investigate the heart and stroke dangers of testosterone-enhancing drugs, 5 lawsuits were filed against Abbott Laboratories and its spinoff AbbVie by men who claimed they suffered heart attacks or strokes after using one of those products, AndroGel.
Puerto Rico built up its pharma manufacturing hub around tax breaks for the industry. But its plants have become more vulnerable to cuts since those tax breaks were phased out, and the island has taken some tough hits in the last year. Now Abbott Laboratories will add to the drain, saying it will close a plant there.
Abbott Laboratories is cutting jobs, with plans to whack a plant in Puerto Rico as well as laying off staff at its Chicago-area headquarters. The company just won't say how many jobs are on the chopping block.
Abbott Laboratories laid off an unspecified number of workers at its headquarters on Tuesday. The decision is part of the company's plan to reduce expenses, according to a statement.
Abbott's diagnostics sales soared during the 2013 fourth quarter and medical device numbers also grew at a moderate clip. As well, emerging-market sales climbed strongly. But net earnings plunged, without the Illinois company's old pharmaceutical business to prop things up.